Hyloris Celebrates Valacyclovir FDA Filing Amid Series Of Announcements

The Belgian Player Disclosed Three New Deals Through February

Following steady updates on its development of a new formulation of valacyclovir, Hyloris revealed the US FDA’s acceptance of its NDA filing while also announcing three new deals this month.

US Food and Drug Administration
(Shutterstock)

The US Food and Drug Administration has accepted Hyloris’ new drug application for its valacyclovir oral liquid amid a flurry of recent announcements made by the Belgian firm.

The FDA set a PDUFA date of 12 October, setting up a potential milestone for the value-added medicines specialist to the second half of the year. The NDA – filed...

More from Value Added Medicines

More from Generics Bulletin